Search

Xiaochun Li

Personal Page: http://134.68.189.178/~XiaochunLi

EDUCATION:

 

POSTDOCTORAL

Centre de Recherches des Mathematiques,

Universite de Montreal and McGill University

Canada

Research Fellow (Statistics)

1997

 

 

 

GRADUATE

University of British Columbia, Canada

University of Saskatchewan, Canada

Tsinghua University, China

Ph.D. (Statistics)

M.Sc. (Statistics)

M.Sc. (Applied Math)

1996

1991

1988

 

 

 

UNDERGRADUATE

Tsinghua University, China

B.Sc. (Applied Math)

1986

 

 

 

APPOINTMENTS:

ACADEMIC

 

Department of Biostatistics, Indiana University School of Medicine

 

Associate Professor

 

 

2007-present

 

Regenstrief Institute

Affiliated Scientist

2007-present

Harvard School of Public Health and Dana Farber Cancer Institute

Research Scientist

2001-2007

 

 

 

NON-ACADEMIC

 

Eli Lilly and Company

Senior Statistician

1997-2001

 

Personal Page: http://134.68.189.178/~XiaochunLi

My curent primary research interest is in developing statistical methods for the analysis of observational data, mostly from eletronic medical records. I have conducted research in statistical methods dealing with confounding with missing data. I have

been involved in research projects in pharmacoepidemiology for drug safety and public health.  I have extensive experience working with a team of medical researchers, biostatisticians and data managers on various database and clinical studies. I am the project lead and co-lead of two industry funded projects on statistical methodology of confounding control and characterization of hypentension patients and management.  I am the Core Leader for the Biostatistics Core of the 2012 Merck-Regenstrief collaboration. My other interests include statistical computing, non- and semi-parametric regression, clinical trials and bioinformatics.

Refereed (Selected)

  1. *Jon Duke, Jeff Friedlin, Xiaochun Li. Consistency in the Safety Labeling of Bioequivalent Medications. Pharmacoepidemiology and Drug Safety. 2012 (Accepted).
  2. * Jon D. Duke, Xu Han, Zhiping Wang, Abhinita Subhadarshini, Shreyas D. Karnik, Xiaochun Li, Stephen D. Hall, Yan Jin, Thomas J. Callaghan, Marcus J. Overhage, David A. Flockhart, Mathew R. Strother, Sara K. Quinney, and Lang Li. Drug Interaction Prediction from Literatures and Clinical Significance Assessment in Medical Record. PLoS Computational Biology (In press, 2012)
  3. *Jason Cadwallader, Chite Asirwa, Xiaochun Li, Joe Kesterson, William M. Tierney, Martin C. Were. Using Computerized Provider Order Entry to Enforce Documentation of Tests with Pending Results at Hospital Discharge. Applied Clinical Informatics. 2012 (Accepted)
  4. * Kahi CJ, Li X, Eckert GJ, Rex DK. High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women. Gastrointest Endosc. 2012 March [2011 Oct 19. Epub ahead of print] PMID: 22018551
  5. * Changyu Shen, Xiaochun Li, Lingling Li and Martin Were. Sensitivity analysis for causal inference using inverse probability weighting. Biometrical Journal. Volume 53, Issue 5, pages 822-837, September, 2011.
  6. * Lingling Li, Changyu Shen, Ann C. Wu and Xiaochun Li. Propensity Score-based Sensitivity Analyses for Unmeasured Confounding. American journal of Epidemiology. Volume 174, Issue 3, pages 345-353, 2011.
  7. * Lingling Li, Changyu Shen, Xiaochun Li and James Robins. On weighting approaches for missing data. Statistical Methods in Medical Research. (2011).
  8. * Xiaochun Li and Changyu Shen. Linkage of Patient Records from Disparate Sources. Statistical Methods in Medical Research (2011). DOI: 10.1177/0962280211403600. PubMed: 21665896
  9. * Were MC, Shen C, Tierney WM, Mamlin JJ, Biondich PG, Li X, Kimaiyo S, Mamlin BW.Evaluation of computer-generated reminders to improve CD4 laboratory monitoring in sub-Saharan Africa: a prospective comparative study. J Am Med Inform Assoc. 2011 Jan 20. [Epub ahead of print]
  10. * Casey, Erin M.; Harb, Wael; Bradford, Daniel; Bufill, Jose; Nattam, Sreenivasa; Patel, Jyoti; Fisher, William; Latz, Jane E.; Li, Xiaochun; Wu, Jingwei; Hanna, Nasser. Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group (LUN06-116). Journal of Thoracic Oncology. 5(11):1815-1820, November 2010.

 



BIOS 621 Advanced Statistical Computing,
Spring


Department of Biostatistics | 410 W. Tenth St., Suite 3000 | Indianapolis, IN 46202 | Ph: (317) 274-2661 | Fax: (317) 274-2678